Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aminacrine is a small molecule antiseptic and anti-infective agent belonging to the acridine class of compounds. It is highly fluorescent and has been used clinically as a topical antiseptic for its slow-acting germicidal properties against bacteria and fungi[2][7]. Aminacrine acts primarily by intercalating into DNA, disrupting nucleic acid function, which underlies both its antimicrobial activity and its use as an experimental mutagen[2][8]. It has also been shown to inhibit the PI3K/AKT/mTOR pathway in tumor cells by downregulating the p110 gamma subunit of phosphoinositide 3-kinase (PI3K), impacting cell survival pathways including p53 and NF-kappaB signaling[6]. Its principal clinical uses have included treatment of vaginal infections such as moniliasis (candidiasis), trichomonal vaginitis, Haemophilus infections, tinea versicolor, mastitis, minor wounds/burns (often in combination with cetrimide), and as a prophylactic agent in gynecological procedures[5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aminacrine.